Bone Biologics Corporation (BBLG) 是一家上市公司 属于 医疗保健 板块，经营于 Medical - Devices 行业. 公司总部位于 Burlington, MA, 美国. 现任CEO为 Jeffrey Frelick.
BBLG 拥有 IPO日期为 2021-10-13, 2 名全职员工, 在 NASDAQ Capital Marke, 市值为 $2.35M.
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
